OS and TNTD in patients treated with CyBorD and ASCT and in those who received CyBorD alone. (A) OS in patients treated with CyBorD and ASCT. (B) OS in patients with a satisfactory response to CyBorD. Six-month landmark plotted OS in patients treated with CyBorD (C) or with CyBorD and ASCT (D) who achieved a VGPR or better. Six-month landmark plotted TNTD in patients who received only CyBorD (E) or CyBorD and ASCT (F).